Protocol Ledger

NCT06044350 · Phase II · ACTIVE NOT RECRUITING

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Interventional Phase II clinical trial protocol NCT06044350 sponsored by Bio-Thera Solutions in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-08-01 Enrollment: 162 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06044350
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)162 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06044350
Protocol FieldVerified Registry Value
NCT IdentifierNCT06044350
Consolidated Lead SponsorBio-Thera Solutions
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment162 participants (ESTIMATED)
Registered Start Date2023-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06044350
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
China-Japan Friendship HospitalBeijing, ChinaOpen Hospital Dossier ->
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen UniversityGuangzhou, ChinaOpen Hospital Dossier ->
Anhui Provincial HospitalHefei, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI